113 related articles for article (PubMed ID: 15317145)
1. Mid-year at the FDA highlights permanent problem.
Howard K
Nat Rev Drug Discov; 2004 Aug; 3(8):637. PubMed ID: 15317145
[No Abstract] [Full Text] [Related]
2. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
3. The numbers game.
Nat Rev Drug Discov; 2002 Dec; 1(12):929. PubMed ID: 12474850
[No Abstract] [Full Text] [Related]
4. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
[TBL] [Abstract][Full Text] [Related]
5. FDA shortened drug approval time in 1995.
Public Health Rep; 1996; 111(4):290. PubMed ID: 8711090
[No Abstract] [Full Text] [Related]
6. Security market reaction to FDA fast track designations.
Anderson CW; Zhang Y
J Health Care Finance; 2010; 37(2):27-48. PubMed ID: 21294437
[TBL] [Abstract][Full Text] [Related]
7. Significant FDA approvals in 2000.
McGinnis TJ
Am Fam Physician; 2001 May; 63(10):2061-4. PubMed ID: 11388719
[No Abstract] [Full Text] [Related]
8. FDA posts record number of drug approvals in 1996.
Am J Health Syst Pharm; 1997 Mar; 54(5):494, 497-8. PubMed ID: 9066856
[No Abstract] [Full Text] [Related]
9. 2007 FDA drug approvals: a year of flux.
Hughes B
Nat Rev Drug Discov; 2008 Feb; 7(2):107-9. PubMed ID: 18246607
[No Abstract] [Full Text] [Related]
10. Making medical progress. A look at FDA approvals in 2000.
FDA Consum; 2001; 35(2):7-8. PubMed ID: 11444251
[No Abstract] [Full Text] [Related]
11. HIV drugs. FDA new drug approval rate lowest in 10 years.
AIDS Policy Law; 2007 Jan; 22(2):5. PubMed ID: 17323437
[No Abstract] [Full Text] [Related]
12. FDA new drug approvals in 2003.
Wynn RL
Gen Dent; 2004; 52(4):294-8, 300. PubMed ID: 15366292
[No Abstract] [Full Text] [Related]
13. 2014 in review: FDA approval of new drugs.
Kinch MS
Drug Discov Today; 2017 Apr; 22(4):620-624. PubMed ID: 26100738
[TBL] [Abstract][Full Text] [Related]
14. The history and contemporary challenges of the US Food and Drug Administration.
Borchers AT; Hagie F; Keen CL; Gershwin ME
Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
[TBL] [Abstract][Full Text] [Related]
15. A drug is not a drug is not a drug: a commentary.
Struijker Boudier HA
Pharmacoepidemiol Drug Saf; 2002 Sep; 11(6):437-8. PubMed ID: 12426926
[No Abstract] [Full Text] [Related]
16. What's the problem with generic antiepileptic drugs?: a call to action.
Berg MJ
Neurology; 2007 Apr; 68(16):1245-6. PubMed ID: 17438211
[No Abstract] [Full Text] [Related]
17. FDA appointee faces angry, demoralized staff.
Fox JL
Nat Biotechnol; 2002 Nov; 20(11):1065. PubMed ID: 12410237
[No Abstract] [Full Text] [Related]
18. Pessimistic response to FDA leadership change.
Kling J
Nat Biotechnol; 2005 Nov; 23(11):1325. PubMed ID: 16273044
[No Abstract] [Full Text] [Related]
19. Communicating with the FDA: the "third rail" of a new model for drug development.
Stanski DR; Orloff JJ
J Clin Pharmacol; 2008 Feb; 48(2):144-5. PubMed ID: 18199890
[No Abstract] [Full Text] [Related]
20. Priority drugs well represented among 1998 approvals. FDA says all performance goals were met.
Miller JL
Am J Health Syst Pharm; 1999 Mar; 56(5):408, 411-2. PubMed ID: 10096697
[No Abstract] [Full Text] [Related]
[Next] [New Search]
